OverviewSuggest Edit
CureVac is a biotechnology company that is active in the field of messenger RNA (mRNA) technology. Using mRNA it is able to directly give the body the information it needs to fight disease. CureVac mainly focuses on three therapeutic areas: cancer immunotherapies, prophylactic vaccines, and protein delivery.
| Type | Private | |
| Founded | 2000 | |
| HQ | Tübingen, DE | Map |
| Website | curevac.com | |
| Employee Ratings | More |
Recent NewsAll News
- CureVac, GSK ink 'pandemic preparedness' agreement through 2029 with German government
- CureVac begins Phase 1 clinical trial for new COVID-19 vaccine
- Worldwide RNA Interference (RNAi) Drug Delivery Industry to 2027 - Players Include Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals and CureVac Among Others
- CureVac starts Phase 1 trial for experimental flu shot developed with GSK
Key People/Management at CureVac
Ingmar Hoerr
Founder
Franz-Werner Haas
CEO
Florian von der Mulbe
Chief Production Officer & Co-Founder
Pierre Kemula
Chief Financial Officer
Mariola Fotin-Mleczek
CTO
Igor Splawski
CSO
CureVac Office Locations
CureVac has offices in Tübingen, Frankfurt am Main and Boston
Tübingen, DE (HQ)
Friedrich-Miescher-Straße 15
Frankfurt am Main, DE
Schumannstr. 27
Tübingen, DE
Paul-Ehrlich-Straße 15
Boston, MA, US
250 Summer St 3rd Fl
CureVac Financials and Metrics
Summary Metrics
Founding Date | 2000 |
CureVac total Funding | $1.1 b |
CureVac latest funding size | $640 m |
Time since last funding | 2 years ago |
CureVac investors | Qatar Investment Authority, Baillie Gifford, DH Capital, Bill & Melinda Gates Foundation, OH Beteiligungen, dievini Hopp Biotech Holding, Baden-Württembergische Versorgungsanstalt für Ärzte, Chartwave, Coppel Family, Landeskreditbank Baden-Württemberg, LBBW Asset Management, Northview LifeSciences, Sigma Group, The European Commission |
CureVac's latest funding round in July 2020 was reported to be $640 m. In total, CureVac has raised $1.1 b. CureVac's latest valuation is reported to be $1.5 b.
CureVac Revenue
CureVac's revenue was reported to be €48.87 m in FY, 2020
| EUR | |
|---|---|
Revenue (Q2, 2022) | 61.8m |
Gross profit (Q2, 2022) | 109.0m |
Net income (Q2, 2022) | (409.8m) |
EBITDA (Q2, 2022) | (395.1m) |
EBIT (Q2, 2022) | (406.8m) |
Market valuation | 1.5b |
Cash (30-Sept-2021) | 1.1b |
EV | 439.0m |
Annual
| EUR | FY, 2018 | FY, 2019 | FY, 2020 |
|---|---|---|---|
Revenue | 12.9m | 17.4m | 48.9m |
Cost of goods sold | (9.1m) | (16.1m) | (2.7m) |
Gross profit | 4.5m | 6.9m | 70.3m |
R&D expense | (40.6m) | (42.8m) | (89.9m) |
Quarterly
| EUR | Q1, 2019 | Q2, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2022 | Q2, 2022 |
|---|---|---|---|---|---|---|---|
Revenue | 3.2m | 1.1m | 3.1m | 32.5m | 5.2m | (29.3m) | 61.8m |
Cost of goods sold | (4.7m) | (7.0m) | (2.4m) | (3.1m) | (2.0m) | (33.6m) | (19.5m) |
Gross profit | (781.0k) | (4.5m) | 2.7m | 33.0m | 7.4m | (84.5m) | 109.0m |
R&D expense | (7.5m) | (5.3m) | (6.9m) | (7.2m) | (34.6m) | 20.2m | (256.5m) |
Annual
| EUR | FY, 2018 | FY, 2019 | FY, 2020 |
|---|---|---|---|
Cash | 21.4m | 30.7m | 1.3b |
Accounts Receivable | 5.5m | 15.7m | 1.0m |
Prepaid Expenses | 2.2m | 1.7m | 40.1m |
Inventories | 3.0m | 6.2m | 14.5m |
Quarterly
| EUR | Q1, 2019 | Q2, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2022 | Q2, 2022 |
|---|---|---|---|---|---|---|---|
Cash | 43.5m | 892.4m | 1.4b | 1.1b | |||
Accounts Receivable | 2.4m | 2.6m | 2.5m | ||||
Prepaid Expenses | 20.0m | 168.2m | |||||
Inventories | 5.4m | 1.4m | 62.9m | 140.9m |
Annual
| EUR | FY, 2018 | FY, 2019 | FY, 2020 |
|---|---|---|---|
Net Income | (71.1m) | (100.1m) | (129.8m) |
Depreciation and Amortization | 3.8m | 4.6m | 10.7m |
Inventories | 878.0k | (3.2m) | (8.3m) |
Quarterly
| EUR | Q1, 2019 | Q2, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2022 | Q2, 2022 |
|---|---|---|---|---|---|---|---|
Net Income | (21.3m) | (23.8m) | (407.9m) | ||||
Depreciation and Amortization | 1.6m | 1.8m | 11.3m | ||||
Inventories | (1.4m) | 772.0k | (143.6m) |
| EUR | FY, 2018 |
|---|---|
Revenue/Employee | 53.3k |
CureVac Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| CureVac Inc. | ||
| CureVac Real Estate GmbH |
CureVac Revenue Breakdown
CureVac revenue breakdown by business segment: 100.0% from PHARMACEUTICAL BIOLOG/VACCINES
CureVac Cybersecurity Score
CureVac Environment, Social & Governance (ESG) Ratings
CureVac Online and Social Media Presence
9 Twitter followers
CureVac has 9 Twitter Followers. The number of followers has increased 9.3% quarter over quarter
CureVac's Trends
CureVac News and Updates
April 11, 2022
CureVac, GSK ink 'pandemic preparedness' agreement through 2029 with German government
Shares of CureVac were up 0.6% in premarket trading on Monday after the company and GlaxoSmithKline said they signed an agreement with the German government for pandemic preparedness that includes mRNA vaccines. As part of the agreement, Germany has access to CureVac's mRNA manufacturing until 202…
March 30, 2022
CureVac begins Phase 1 clinical trial for new COVID-19 vaccine
Shares of CureVac were up 1.2% in premarket trading on Wednesday after the company said it dosed the first participant in a Phase 1 clinical trial for the new mRNA COVID-19 vaccine it's developing with GlaxoSmithKline . The study is being conducted in the U.S. and is set to enroll 210 adults. The c…
March 08, 2022
Worldwide RNA Interference (RNAi) Drug Delivery Industry to 2027 - Players Include Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals and CureVac Among Others
Dublin, March 08, 2022 (GLOBE NEWSWIRE) -- The "Worldwide RNA Interference (RNAi) Drug Delivery" report has been added to ResearchAndMarkets.com's offering. The global RNA interference (RNAi) drug delivery market reached a value of US$ 54.74 Billion in 2021. Looking forward, the publisher expects …
February 10, 2022
CureVac starts Phase 1 trial for experimental flu shot developed with GSK
Shares of CureVac gained 2.6% in premarket trading on Thursday after the company said it began dosing participants in a Phase 1 clinical trial assessing an experimental mRNA-based influenza vaccine it developed with GlaxoSmithKline . The open-label study plans to enroll 240 adults. CureVac had prev…
November 10, 2021
CureVac cites 'promising' data for its investigational cancer injection
Shares of CureVac gained 3.5% in premarket trading on Wednesday after the company shared what it called promising data for its experimental cancer shot in a Phase 1 clinical trial. The injection is being tested in 58 patients with advanced cutaneous melanoma, adenoid cystic carcinoma, and certain t…
October 12, 2021
CureVac stops development of its COVID-19 shot, will focus on new COVID-19 vaccine set for 2022
Shares of CureVac tumbled 9.6% in premarket trading on Tuesday after the German biopharmaceutical company said it will scrap development of its COVID-19 vaccine candidate and instead focus on developing second-generation mRNA shots against COVID-19 with GlaxoSmithKline . The existing purchase agree…
CureVac Blogs
June 24, 2021
[English only] CureVac Announces Voting Results of General Meeting
The post [English only] CureVac Announces Voting Results of General Meeting appeared first on CureVac.
March 30, 2021
[English only] Celonic and CureVac Announce Agreement to Manufacture over 100 Million Doses of CureVac’s COVID-19 Vaccine Candidate, CVnCoV
The post [English only] Celonic and CureVac Announce Agreement to Manufacture over 100 Million Doses of CureVac’s COVID-19 Vaccine Candidate, CVnCoV appeared first on CureVac.
CureVac Frequently Asked Questions
When was CureVac founded?
CureVac was founded in 2000.
Who are CureVac key executives?
CureVac's key executives are Ingmar Hoerr, Franz-Werner Haas and Florian von der Mulbe.
How many employees does CureVac have?
CureVac has 400 employees.
What is CureVac revenue?
Latest CureVac annual revenue is €48.9 m.
What is CureVac revenue per employee?
Latest CureVac revenue per employee is €122.2 k.
Who are CureVac competitors?
Competitors of CureVac include Stemirna, RNACure and RNAimmune.
Where is CureVac headquarters?
CureVac headquarters is located at Friedrich-Miescher-Straße 15, Tübingen.
Where are CureVac offices?
CureVac has offices in Tübingen, Frankfurt am Main and Boston.
How many offices does CureVac have?
CureVac has 4 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies